# The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer

> **NCT03889626** · PHASE3 · UNKNOWN · sponsor: **Fudan University** · enrollment: 242 (estimated)

## Conditions studied

- Stomach Neoplasms
- Gastrointestinal Neoplasms
- Stomach Diseases
- Digestive System Neoplasms
- Capecitabine
- Apatinib
- Neoplasms
- Molecular Mechanisms of Pharmacological Action

## Interventions

- **DRUG:** Apatinib
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT03889626
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-03-22
- **Primary completion:** 2022-03-22
- **Final completion:** 2024-03-22
- **Target enrollment:** 242 (ESTIMATED)
- **Last updated:** 2019-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03889626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03889626, "The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT03889626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*